Announced details
Cancer immunotherapy for glioblastoma and brain tumors
The conference at which HEALIOS K.K. will present its research results as a poster. Dual CAR-eNK® cells are being developed by HEALIOS and its development partner, Akatsuki Therapeutics.
An annual scientific meeting to be held in Osaka from 17 to 19 November 2026. The venue is Grand Cube Osaka (Osaka International Convention Center).
HEALIOS K.K. Kobe Research Institute
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
55th Annual Meeting of the Japanese Society for Immunology
| Item | Details |
|---|---|
| Names of Products / Services Covered | Dual CAR-eNK® cells, CAR-eNK® cells, and eNK® cells (development code: AKT-01/HLCN061) |
| Counterparty | Japanese Society for Immunology Annual Meeting (55th) |
| Counterparty overview | An annual scientific meeting to be held in Osaka from 17 to 19 November 2026. The venue is Grand Cube Osaka (Osaka International Convention Center). |
| Relationship with the Company | The conference at which HEALIOS K.K. will present its research results as a poster. Dual CAR-eNK® cells are being developed by HEALIOS and its development partner, Akatsuki Therapeutics. |
| Launch date | 17 November 2026 (scheduled; date of the research poster presentation) |
| Applicable area | Cancer immunotherapy for glioblastoma and brain tumors |
| Location | HEALIOS K.K. Kobe Research Institute |
| Source | 55th Annual Meeting of the Japanese Society for Immunology |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To present the research results at the 55th Annual Meeting of the Japanese Society for Immunology.